Neurocrine Biosciences (NBIX) Deferred Taxes (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Deferred Taxes of -$25.3 million for Q2 2026, up 32.35% year-over-year from -$19.1 million in Q2 2025, and up 58.59% on a QoQ basis from -$61.1 million in Q1 2026.
Neurocrine Biosciences (NBIX) Deferred Taxes (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Deferred Taxes for 16 years, with the latest figure at -$25.3 million in Q2 2026.
- Deferred Taxes for Q2 2026 came in at -$25.3 million, up 32.35% year-over-year; the trailing twelve-month figure through Jun 2026 was $130.1 million (up 210.91% YoY), and the FY2025 annual result was $165.4 million, up 234.36% from the prior year.
- Deferred Taxes climbed to -$25.3 million in Q2 2026, from -$61.1 million in the prior quarter.
- Over five years, Deferred Taxes peaked at $168.3 million in Q3 2025 and troughed at -$61.1 million in Q1 2026.
- A 5-year average of -$4.5 million and a median of -$14.6 million in 2024 frame the typical range for Deferred Taxes.
- The widest annual swing landed in 2023, when Deferred Taxes slumped 10433.33%; it then soared 582.23% in 2025.
- A 5-year view of Deferred Taxes shows it stood at $13.5 million in 2022, then surged by 52.59% to $20.6 million in 2023, then slumped by 251.94% to -$31.3 million in 2024, then soared by 253.99% to $48.2 million in 2025, then tumbled by 152.49% to -$25.3 million in 2026.
- Per Business Quant data, the three most recent Deferred Taxes figures were -$25.3 million in Q2 2026, -$61.1 million in Q1 2026, and $48.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 25.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -33.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 25.70 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -124.50 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | -25.30 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 9.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.30 Mn |
| Mar 31, 2026 | -61.10 Mn |
| Dec 31, 2025 | 48.20 Mn |
| Sep 30, 2025 | 168.30 Mn |
| Jun 30, 2025 | -37.40 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -31.30 Mn |
| Sep 30, 2024 | -34.90 Mn |
| Jun 30, 2024 | -41.30 Mn |
| Mar 31, 2024 | -15.60 Mn |
| Dec 31, 2023 | 20.60 Mn |
| Sep 30, 2023 | -4.20 Mn |
| Jun 30, 2023 | -41.50 Mn |
| Mar 31, 2023 | -31.60 Mn |
| Dec 31, 2022 | 13.50 Mn |
| Sep 30, 2022 | 9.00 Mn |
| Jun 30, 2022 | -3.10 Mn |
| Mar 31, 2022 | -300,000.00 |
| Dec 31, 2021 | -4.70 Mn |
| Sep 30, 2021 | 5.70 Mn |